Navigation Links
Radi Medical Systems Announces Schedule for TCT 2008
Date:10/8/2008

FFR Case Review With Drs. William F. Fearon, Morton J. Kern and Peter Ver

Lee Among the Highlights

WILMINGTON, Massachusetts, October 8 /PRNewswire/ -- The use of fractional flow reserve (FFR) for optimizing patient outcomes is the topic of multiple sessions at this year's Transcatheter Cardiovascular Therapeutics symposium, TCT 2008, which will take place Oct. 12-17 in Washington, D.C.

Radi Medical Systems, the first company to develop systems that calculate FFR with the physiologic assessment of targeted lesions, is sponsoring a breakfast session, "Intervention Under Pressure: Discovering the best way with FFR," at 7 a.m. EDT on Tuesday, Oct. 14, in room 150 B at the Washington Convention Center. During the session, William F. Fearon, M.D., of Stanford University, will discuss FFR measurement in multi vessel disease, Morton J. Kern, M.D., of the University of California, Irvine, will speak about FFR measurement in challenging lesion subsets, and Peter Ver Lee, M.D., of the Eastern Maine Medical Center, will provide an overview of FFR measurement in private practice.

Following the session, data from the study titled "Fractional flow reserve vs. Angiography for Multivessel Evaluation" (FAME) will be presented by Dr. Fearon and Nico Pijls, M.D., Ph.D., in the Main Arena at 11:45 a.m. EDT. FAME is the world's first randomized, prospective, multicenter trial to compare clinical outcomes and the cost-effectiveness of a physiologic-guided percutaneous coronary intervention (PCI) strategy to an angiographic-guided one in patients with multi vessel coronary artery disease

"We are excited to discuss topics pertaining to fractional flow reserve measurement, a few hours before data from the FAME study is presented in the Main Arena," said Jason Rudy, Director of Marketing of Radi Medical Systems Inc. "We anticipate that these will be two engaging sessions that educate about the benefits of FFR use in today's cathlab."

Radi Medical Systems will be exhibiting at booth 1203 and will displaying their most recent PressureWire(R) system and updated FemoStop(R) Gold Femoral Compression System.

About Fractional Flow Reserve, FFR

Fractional Flow Reserve (FFR) is an index for functional severity of coronary stenosis, measured by PressureWire(R). FFR is 100% specific in identifying which lesion or lesions are responsible for a patient's ischemia and it is used by the interventional cardiologist to direct coronary interventions and assess results for improved treatment outcomes.

About Radi Medical Systems AB

Radi Medical Systems AB (Radi) develops, manufactures and sells medical devices designed to improve patient care. The company's pioneering work in the field of interventional cardiology has resulted in market-leading intravascular sensors and hemostasis management and radiology devices. Radi works closely with medical practitioners to develop solutions that address clinical needs, as well as provide clinical education support. Founded in 1988, Radi employs more than 380 people globally and has representation in more than 40 countries. The company is based in Uppsala, Sweden, and maintains a U.S. headquarters in Wilmington, Mass. For more information, visit http://www.radi.se.


'/>"/>
SOURCE Radi Medical Systems AB
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
5. BioMS Medical announces its intention to renew a normal course issuer bid
6. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Globus Medical Announces Record 2nd Quarter 2007 Results
10. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
11. China Medical Technologies Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... and HAMILTON, Bermuda , Feb. ... ADXS ) and SELLAS Life ... on developing cancer immunotherapies, today announced that Advaxis ... novel cancer immunotherapy agent using Advaxis, proprietary ... WT1 targeted heteroclitic peptide antigen mixture (galinpepimut-S). ...
(Date:2/27/2017)... ... ... The Catalyst Midwest premix manufacturing facility has been certified as ... private label organic services. , The first organic product is Organic 18 Percent Layer ... Dynamite Marketing, which owns the facility. , Catalyst already has received the Safe ...
(Date:2/24/2017)... ... February 24, 2017 , ... A ... safely completed in an ambulatory surgery center (ASC) with satisfactory clinical and patient-reported ... two-year TDR studies. , Jake Lubinski, president of AxioMed, commented on the ...
(Date:2/24/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today is ... in its previously announced rights offering of up ... common stock and Series C Convertible Preferred Stock ... As previously announced, the rights ...
Breaking Biology Technology:
(Date:2/14/2017)... 14, 2017  Wake Forest Baptist Medical Center today ... chief executive officer (CEO). Freischlag joins the medical center ... McConnell , M.D., who last year announced that he ... Center, after leading it since 2008.   ... Wake Forest Baptist,s academic health system, which includes Wake ...
(Date:2/10/2017)... 10, 2017 Research and Markets ... "Personalized Medicine - Scientific and Commercial Aspects" to their ... ... is integrated with therapy for selection of treatment as well ... and prevention of disease in modern medicine. Biochip/microarray technologies and ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
Breaking Biology News(10 mins):